These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 16631535

  • 1. Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.
    Drel VR, Pacher P, Stevens MJ, Obrosova IG.
    Free Radic Biol Med; 2006 Apr 15; 40(8):1454-65. PubMed ID: 16631535
    [Abstract] [Full Text] [Related]

  • 2. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
    Obrosova IG, Pacher P, Szabó C, Zsengeller Z, Hirooka H, Stevens MJ, Yorek MA.
    Diabetes; 2005 Jan 15; 54(1):234-42. PubMed ID: 15616034
    [Abstract] [Full Text] [Related]

  • 3. Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis.
    Drel VR, Pacher P, Ali TK, Shin J, Julius U, El-Remessy AB, Obrosova IG.
    Int J Mol Med; 2008 Jun 15; 21(6):667-76. PubMed ID: 18506358
    [Abstract] [Full Text] [Related]

  • 4. Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose.
    Liu W, Liu P, Tao S, Deng Y, Li X, Lan T, Zhang X, Guo F, Huang W, Chen F, Huang H, Zhou SF.
    Arch Biochem Biophys; 2008 Jul 15; 475(2):128-34. PubMed ID: 18471986
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina.
    Obrosova IG, Maksimchyk Y, Pacher P, Agardh E, Smith ML, El-Remessy AB, Agardh CD.
    Int J Mol Med; 2010 Jul 15; 26(1):135-42. PubMed ID: 20514433
    [Abstract] [Full Text] [Related]

  • 11. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats.
    Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ.
    Diabetes; 2003 Mar 15; 52(3):864-71. PubMed ID: 12606532
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Role of poly(ADP-ribose) polymerase activation in the pathogenesis of periodontitis in diabetes.
    Adachi K, Miyajima SI, Nakamura N, Miyabe M, Kobayashi Y, Nishikawa T, Suzuki Y, Kikuchi T, Kobayashi S, Saiki T, Mizutani M, Ohno N, Noguchi T, Mitani A, Matsubara T, Naruse K.
    J Clin Periodontol; 2017 Oct 15; 44(10):971-980. PubMed ID: 28570002
    [Abstract] [Full Text] [Related]

  • 15. Rapid 'glycaemic swings' induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus.
    Horváth EM, Benko R, Kiss L, Murányi M, Pék T, Fekete K, Bárány T, Somlai A, Csordás A, Szabo C.
    Diabetologia; 2009 May 15; 52(5):952-61. PubMed ID: 19263033
    [Abstract] [Full Text] [Related]

  • 16. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy.
    Obrosova IG, Li F, Abatan OI, Forsell MA, Komjáti K, Pacher P, Szabó C, Stevens MJ.
    Diabetes; 2004 Mar 15; 53(3):711-20. PubMed ID: 14988256
    [Abstract] [Full Text] [Related]

  • 17. Increased renal aldose reductase activity, immunoreactivity, and mRNA in streptozocin-induced diabetic rats.
    Ghahary A, Luo JM, Gong YW, Chakrabarti S, Sima AA, Murphy LJ.
    Diabetes; 1989 Aug 15; 38(8):1067-71. PubMed ID: 2526763
    [Abstract] [Full Text] [Related]

  • 18. New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-{alpha}.
    Drel VR, Lupachyk S, Shevalye H, Vareniuk I, Xu W, Zhang J, Delamere NA, Shahidullah M, Slusher B, Obrosova IG.
    Endocrinology; 2010 Jun 15; 151(6):2547-55. PubMed ID: 20357221
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy.
    Stavniichuk R, Shevalye H, Hirooka H, Nadler JL, Obrosova IG.
    Biochem Pharmacol; 2012 Apr 01; 83(7):932-40. PubMed ID: 22285226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.